Our Doctors
Meet all the doctors from Cleveland Clinic Abu Dhabi.
View Doctors
Could you help us transform the future of neurological care? We are looking for participants to take part in the UAE-PRIME Trial, a groundbreaking study focused on advancing brain technology and improving the lives of those affected by paralysis and speech impairment.
Cleveland Clinic Abu Dhabi, in collaboration with the Department of Health – Abu Dhabi and in partnership with Neuralink, has launched the region’s first human brain-computer interface (BCI) study – the UAE-PRIME trial.
BCIs, such as the Neuralink N1 Implant, allow individuals with severe paralysis and speech impairment to control devices and interact with the digital world using only their thoughts, restoring communication and independence.
Redefining neurological care, the study reflects Cleveland Clinic Abu Dhabi’s commitment to cutting-edge clinical innovation and life-changing patient outcomes and underscores our role as a regional and global leader in advanced neuroscience and digital health.
Cleveland Clinic Abu Dhabi is looking for people to take part in the study (see eligibility criteria below). If you want to learn more about the trial, and how we are contributing to the global advancement of BCI technology, please fill out and submit the below form.
The Neuralink N1 Implant is a fully implantable, wireless BCI designed to help individuals with paralysis and speech impairment to control external devices and communicate more independently with their thoughts. The implant records brain signals via 1,024 electrodes distributed across ultra-thin threads, each finer than a human hair. The threads are precisely inserted into the brain using the Neuralink R1 Robot.
Once in place, the N1 Implant detects brain signals corresponding to intentions, such as intended movement or speech, and transmits them wirelessly to an external app. The app decodes these signals into digital commands, allowing direct communication between the brain and digital devices, using only thoughts.
UAE-PRIME is a feasibility study that aims to evaluate the safety and functionality of Neuralink’s N1 Implant. Participants will use the device over a period of one year, with the option to continue using the device for an additional three years, with a focus on evaluating the implant’s safety and functionality in a real-world environment.
Ideal candidates include adults (18+) with severe physical disabilities resulting in limited limb movement or speech. This may include people with:
Cognitive function must remain intact, with candidates able to produce motor-related thoughts or internal speech. All candidates will undergo a thorough screening process which will include psychological evaluations, brain imaging, and exclusion of major co-morbidities (such a traumatic brain injury, brain implants like VP shunts or DBS, uncontrolled diabetes, morbid obesity, or bleeding disorders).
Implantation is a neurosurgical procedure which involves a small circular skull opening approximately 25 mm in diameter to fit around the body of the N1 Implant. The opening is created over a specific area of the brain and its location is determined pre-operatively using neuro-navigation guided by a functional MRI. After exposing the brain, the threads of the implant are robotically inserted into a small (~2x2 cm) exposed area.
The entire procedure takes approximately 3 to 4 hours, during which threads of the N1 Implant are inserted into the brain, the N1 Implant is fixated into the skull, and the incision is closed. Patients are generally discharged the next day.
After implantation, patients will have routine BCI research sessions to practice using their N1 Implant. Patients are expected to:
After the first year, patients can choose to continue using, deactivate, or remove the implant based on medical outcomes and personal preferences.
This is a research study, and while there are no guaranteed benefits, participants may experience significant improvements in independence and digital communication, including the ability to:
For those with paralysis or impaired speech, the trial represents a transformational shift in autonomy and engagement with the world.
For more details on Neuralink, please visit: neuralink.com.
For anyone wishing to participate in the UAE trial, please fill out the pre-screening and submit the form here: UAE-PRIME Study Pre-Screening Questionnaire
© Copyright 2025 Cleveland Clinic Abu Dhabi. All rights reserved.
This page has been reviewed by a medical professional from Cleveland Clinic Abu Dhabi. Information on this page is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.
Learn more about our editorial process here.
We’re here to make managing your healthcare easier.